This product is an active protein and may elicit a biological response in vivo, handle with caution.
Apoptosis Inhibitor 3
Baculoviral IAP repeat containing 4
Baculoviral IAP Repeat Containing Protein 4
Baculoviral IAP repeat-containing protein 4
E3 ubiquitin-protein ligase XIAP
IAP like protein
Inhibitor of apoptosis protein 3
Inhibitor of Apoptosis X Linked
Mammalian IAP Homologue A
X linked IAP
X linked inhibitor of apoptosis
X linked inhibitor of apoptosis E3 ubiquitin protein ligase
X linked inhibitor of apoptosis protein
X-linked inhibitor of apoptosis protein
Apoptotic suppressor. Has E3 ubiquitin-protein ligase activity. Mediates the proteasomal degradation of target proteins, such as caspase-3, SMAC or AIFM1. Inhibitor of caspase-3, -7 and -9. Mediates activation of MAP3K7/TAK1, leading to the activation of NF-kappa-B.
Ubiquitous, except peripheral blood leukocytes.
Involvement in disease
Defects in XIAP are the cause of lymphoproliferative syndrome X-linked type 2 (XLP2) [MIM:300635]. XLP is a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr virus (EBV). Symptoms include severe or fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia and malignant lymphoma.
Belongs to the IAP family. Contains 3 BIR repeats. Contains 1 RING-type zinc finger.
The first BIR domain is involved in interaction with TAB1/MAP3K7IP1 and is important for dimerization. The second BIR domain is sufficient to inhibit caspase-3 and caspase-7, while the third BIR is involved in caspase-9 inhibition. The interactions with SMAC and PRSS25 are mediated by the second and third BIR domains.
Ubiquitinated and degraded by the proteasome in apoptotic cells. Phosphorylation by PKB/AKT protects XIAP against ubiquitination and protects the protein against proteasomal degradation.